Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 11, 2022

SELL
$53.19 - $79.24 $398,925 - $594,300
-7,500 Closed
0 $0
Q4 2021

Feb 09, 2022

SELL
$70.09 - $111.29 $561,140 - $890,987
-8,006 Reduced 51.63%
7,500 $568,000
Q3 2021

Nov 09, 2021

BUY
$110.2 - $156.64 $655,469 - $931,694
5,948 Added 62.23%
15,506 $1.74 Million
Q2 2021

Aug 12, 2021

SELL
$100.84 - $161.89 $406,586 - $652,740
-4,032 Reduced 29.67%
9,558 $1.55 Million
Q1 2021

May 10, 2021

SELL
$110.72 - $210.04 $4,318 - $8,191
-39 Reduced 0.29%
13,590 $1.66 Million
Q4 2020

Feb 16, 2021

BUY
$79.67 - $173.23 $269,045 - $584,997
3,377 Added 32.94%
13,629 $2.09 Million
Q3 2020

Nov 13, 2020

SELL
$78.5 - $100.64 $29,280 - $37,538
-373 Reduced 3.51%
10,252 $857,000
Q2 2020

Aug 13, 2020

BUY
$38.5 - $76.05 $409,062 - $808,031
10,625 New
10,625 $781,000
Q4 2018

Feb 14, 2019

SELL
$22.73 - $42.34 $251,621 - $468,703
-11,070 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$44.35 - $65.71 $319,985 - $474,097
-7,215 Reduced 39.46%
11,070 $491,000
Q2 2018

Aug 13, 2018

BUY
$42.62 - $73.59 $779,306 - $1.35 Million
18,285 New
18,285 $1.07 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.1B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track L & S Advisors Inc Portfolio

Follow L & S Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of L & S Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on L & S Advisors Inc with notifications on news.